AG
RNAC icon

Algert Global’s Cartesian Therapeutics RNAC Stock Holding History

Algert Global’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-729
Closed -$99K – 511
2021
Q1 		$99K Hold
729
– – 0.03% 411
2020
Q4 		$66K Hold
729
– – 0.02% 392
2020
Q3 		$54K Hold
729
– – 0.02% 375
2020
Q2 		$62K Buy
+729
New +$66.1K 0.02% 390

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Algert Global's RNAC Position: Q2 2021 in Review

Algert Global sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 729 shares — an estimated $99K sold.

Algert Global first reported a position in RNAC in Q2 2020 and held it in 4 quarters. The position peaked at $99K in Q1 2021. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

  • Algert Global reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Algert Global sold 729 Cartesian Therapeutics shares in Q2 2021, an estimated $99K.
  • Algert Global first reported a position in Cartesian Therapeutics in Q2 2020 and held it in 4 quarters.
  • Algert Global's Cartesian Therapeutics position peaked at $99K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on Algert Global's 13F filing for Q2 2021, filed 13 Aug 2021.